Obinutuzumab
UTX-TGR-304
Phase 3 mab terminated
Quick answer
Obinutuzumab for Chronic Lymphocytic Leukemia is a Phase 3 program (mab) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated